JP2018533589A5 - - Google Patents

Download PDF

Info

Publication number
JP2018533589A5
JP2018533589A5 JP2018522753A JP2018522753A JP2018533589A5 JP 2018533589 A5 JP2018533589 A5 JP 2018533589A5 JP 2018522753 A JP2018522753 A JP 2018522753A JP 2018522753 A JP2018522753 A JP 2018522753A JP 2018533589 A5 JP2018533589 A5 JP 2018533589A5
Authority
JP
Japan
Prior art keywords
plasminogen
subject
drug
days
deficient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018522753A
Other languages
English (en)
Japanese (ja)
Other versions
JP6878423B2 (ja
JP2018533589A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/001599 external-priority patent/WO2017077380A1/en
Publication of JP2018533589A publication Critical patent/JP2018533589A/ja
Publication of JP2018533589A5 publication Critical patent/JP2018533589A5/ja
Application granted granted Critical
Publication of JP6878423B2 publication Critical patent/JP6878423B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018522753A 2015-11-03 2016-11-03 プラスミノーゲン欠損症のためのプラスミノーゲン補充療法 Active JP6878423B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562250235P 2015-11-03 2015-11-03
US62/250,235 2015-11-03
PCT/IB2016/001599 WO2017077380A1 (en) 2015-11-03 2016-11-03 Plasminogen replacement therapy for plasminogen-deficiency

Publications (3)

Publication Number Publication Date
JP2018533589A JP2018533589A (ja) 2018-11-15
JP2018533589A5 true JP2018533589A5 (enExample) 2019-12-12
JP6878423B2 JP6878423B2 (ja) 2021-05-26

Family

ID=58661917

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018522753A Active JP6878423B2 (ja) 2015-11-03 2016-11-03 プラスミノーゲン欠損症のためのプラスミノーゲン補充療法

Country Status (24)

Country Link
US (1) US11291711B2 (enExample)
EP (1) EP3370760B1 (enExample)
JP (1) JP6878423B2 (enExample)
KR (1) KR102821400B1 (enExample)
CN (1) CN108289935A (enExample)
AU (1) AU2016347863B2 (enExample)
BR (1) BR112018008965A8 (enExample)
CA (1) CA3002915C (enExample)
DK (1) DK3370760T3 (enExample)
ES (1) ES3055824T3 (enExample)
FI (1) FI3370760T3 (enExample)
IL (1) IL258913B (enExample)
LT (1) LT3370760T (enExample)
MX (1) MX2018005588A (enExample)
MY (1) MY199581A (enExample)
PL (1) PL3370760T3 (enExample)
PT (1) PT3370760T (enExample)
RS (1) RS67519B1 (enExample)
RU (1) RU2736831C2 (enExample)
SI (1) SI3370760T1 (enExample)
SM (1) SMT202500451T1 (enExample)
TW (1) TWI801331B (enExample)
WO (1) WO2017077380A1 (enExample)
ZA (1) ZA201802820B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201722464A (zh) * 2015-11-10 2017-07-01 波麥堤克生化科學有限公司 用於傷口癒合之纖維蛋白溶酶原給藥方案
CN115845037A (zh) * 2015-12-18 2023-03-28 泰伦基国际有限公司 一种用于预防或治疗急性及慢性血栓的方法
CN108778307A (zh) 2015-12-18 2018-11-09 泰伦基国际有限公司 一种预防和治疗糖尿病肾病的方法
TWI653981B (zh) 2015-12-18 2019-03-21 深圳瑞健生命科學硏究院有限公司 Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury
US11338022B2 (en) 2015-12-18 2022-05-24 Talengen International Limited Method for preventing and treating angiocardiopathy
US12011455B2 (en) 2016-03-17 2024-06-18 Vanderbilt University Enhancing plasmin activity to prevent soft tissue calcification
US11129880B2 (en) * 2016-12-15 2021-09-28 Talengen International Limited Method for promoting insulin secretion
TW201822805A (zh) * 2016-12-15 2018-07-01 深圳瑞健生命科學硏究院有限公司 一種預防和治療脂肪異常沉積導致的組織損傷的方法
EP3556385A4 (en) 2016-12-15 2020-12-30 Talengen International Limited PROCESS FOR ALLEGING HEART DISEASE
TW201829448A (zh) 2016-12-15 2018-08-16 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
US11219669B2 (en) 2016-12-15 2022-01-11 Talengen International Limited Method for preventing and treating liver fibrosis
CN109125715A (zh) * 2017-06-19 2019-01-04 深圳瑞健生命科学研究院有限公司 一种调控glp-1/glp-1r的方法和药物
US11938172B2 (en) 2017-06-19 2024-03-26 Talengen International Limited Method for regulating and controlling GLP-1/GLP-1R and drug
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
EP3914288A1 (en) 2019-01-24 2021-12-01 PreviPharma Consulting GmbH Plasminogen for treating and preventing microthrombosis
EP3812772B1 (en) * 2019-10-24 2025-02-19 Hôpitaux Universitaires de Strasbourg (HUS) Method for diagnosing fibrinolytic insufficiency related to neutrophil extracellular traps
US12497607B2 (en) * 2020-04-23 2025-12-16 Previpharma Consulting Gmbh Plasminogen for use in treating and preventing lung dysfunction
CN114354929A (zh) * 2022-01-07 2022-04-15 南京鼓楼医院 一种用于监测人体纤溶状态的试剂盒及应用
WO2025049724A1 (en) * 2023-08-29 2025-03-06 Board Of Regents Of The University Of Nebraska Compositions and methods for treating pleural space infections and hemothorax

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2254316B1 (enExample) * 1973-12-18 1977-04-22 Choay Sa
JP2764264B2 (ja) * 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
AT402367B (de) * 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen
AU4661493A (en) * 1992-07-01 1994-01-31 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
WO1994018315A1 (en) * 1993-02-05 1994-08-18 Vascular Laboratories, Inc. Use of intra-platelet urokinase-type plasminogen activators for long-term inhibition of thrombosis
US20030224516A1 (en) * 2002-06-03 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of prox-1 expression
US7067492B2 (en) * 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
US20050271636A1 (en) * 2002-08-09 2005-12-08 St. Jude Children's Research Hospital, Inc. Diagnostic and therapeutic uses for prox 1
GB0509438D0 (en) * 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
WO2008027000A2 (en) * 2006-08-28 2008-03-06 Omnio Healer Ab Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
WO2008026999A2 (en) * 2006-08-28 2008-03-06 Omnio Healer Ab Candidates against infection
EP2451835A1 (en) * 2009-07-10 2012-05-16 ThromboGenics N.V. Variants of plasminogen and plasmin
WO2012074588A2 (en) * 2010-08-30 2012-06-07 President And Fellows Of Harvard College Shear controlled release for stenotic lesions and thrombolytic therapies
PY1577621A (es) 2014-12-19 2017-10-02 Prometic Biotherapeutics Inc Composicion farmaceutica que comprende plasminogeno y uso para el mismo
TWI624267B (zh) * 2015-12-18 2018-05-21 Talengen Institute Of Life Sciences Co Ltd 纖溶酶原在製備預防或治療糖尿病性視網膜病變的藥劑上的用途及包括纖溶酶原用於預防或治療糖尿病性視網膜病變之藥劑

Similar Documents

Publication Publication Date Title
RU2018120182A (ru) Плазминоген-заместительная терапия при дефиците плазминогена
EP2635269B1 (en) A combination composition
Kelly et al. Beta-adrenergic agonists for acute, severe asthma
Kumar et al. The syndrome of irreversible acidosis after prolonged propofol infusion
ES2971959T3 (es) Terlipresina para el tratamiento de la ascitis debida a cirrosis hepática administrada como una infusión continua
JP2013541583A5 (enExample)
AU2011274652B2 (en) A combination composition comprising ibuprofen and paracetamol
Fabi et al. Are nasal decongestants safer than rhinitis? A case of oxymetazoline-induced syncope
EP3393517B1 (en) Acetylsalicylic acid for use in the treatment of moderate to severe influenza
JP2020531568A5 (enExample)
Kurachek et al. Inadvertent intravenous administration of racemic epinephrine
Akca et al. Nebulized epinephrine treatment in pediatric emergency department
EP3906934B1 (en) Application of dalargin for the prevention of viral respiratory infections and prevention of the development of complications during viral respiratory infections
Walsh et al. A pediatric case study of treprostinil overdose
Brønstad et al. Fatal propofol infusion syndrome in a young man with status epilepticus.
Zhou et al. anesthesia care by
Graff et al. Chloroquine Ingestion to Prevent SARS-CoV-2 Infection: A Report of Two Cases
Hwang et al. Serotonin syndrome induced by drug interaction of isoniazid and metoclopramide
Aranda et al. Biodistribution Of [f-18] Fdg-Labeled Adult Bone Marrow-Derived Mesenchymal Stromal Cells With Pet/ct Scan In An Ards Sheep Model
Nagaraj NEUROLEPTIC MALIGNANT SYNDROME IN A CHILD WITH ORGANOPHOSPHORUS POISONING
Pavcnik-Arnol et al. SEDATION WITH SEVOFLURANE DELIVERED BY THE ANESTHETIC CONSERVING DEVICE ANACONDA® IN THE PEDIATRIC INTENSIVE CARE UNIT
Yamamoto et al. Heart Rate Response to Intravenous Landiolol during Propofol Anesthesia
Nagaraj INTERMITTENT BOLUS REGIMEN OF PROPOFOL IN CHILDREN REQUIRING SEDATION FOR AMBULATORY MAGNETIC RESONANCE IMAGING (MRI)
Haitsma et al. Surfactant Therapy
Aburawi Epinephrine overdose